申请人:Amegadzie Kudzovi Albert
公开号:US20050239776A1
公开(公告)日:2005-10-27
The present invention relates to selective NK-1 receptor antagonists of Formula (I); or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.
本发明涉及选择性NK-1受体拮抗剂的公式(I)或其药学上可接受的盐,用于治疗与过多的速激肽相关的疾病。